Compare EDAP & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDAP | ACOG |
|---|---|---|
| Founded | 1979 | 2000 |
| Country | France | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.6M | 129.4M |
| IPO Year | 1997 | N/A |
| Metric | EDAP | ACOG |
|---|---|---|
| Price | $4.13 | $5.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 76.0K | 61.5K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,853,925.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.67 | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.61 | N/A |
| 52 Week Low | $1.21 | $3.75 |
| 52 Week High | $4.29 | $11.54 |
| Indicator | EDAP | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 37.16 |
| Support Level | $3.44 | $5.20 |
| Resistance Level | $4.28 | $5.97 |
| Average True Range (ATR) | 0.35 | 0.45 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 83.19 | 5.48 |
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.